A novel antibiotic therapy for Clostridioides difficile infection, currently dubbed CRS3123, has demonstrated narrower selectivity and reduced bacterial derangement in the gut compared with other antibiotics.
A new study that looked at 7 billion trips to healthcare centers found that antibiotics continue to be far overprescribed, especially among Black and senior patients.